Day: March 20, 2013

Rivaroxaban approved for the treatment of DVT and PE

In early November 2012, the FDA expanded the approved use of rivaroxaban (brand name Xarelto) to be used for the treatment of blood clots in deep veins (deep venous thrombosis, DVT) and in pulmonary arteries (pulmonary embolism, PE).  Rivaroxaban was originally approved for the treatment of patients with atrial fibrillation. DVT and PE are major health concerns […]